Roche Holding AG (RHHBY)
32.81
+0.16
(+0.49%)
USD |
OTCM |
May 17, 16:00
Roche Accounts Payable (Quarterly): 4.196B for Dec. 31, 2023
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 4.196B |
June 30, 2023 | 4.509B |
June 30, 2023 | 4.509B |
December 31, 2022 | 4.164B |
June 30, 2022 | 4.082B |
June 30, 2022 | 4.082B |
December 31, 2021 | 4.205B |
June 30, 2021 | 4.605B |
June 30, 2021 | 4.605B |
December 31, 2020 | 3.797B |
June 30, 2020 | 3.198B |
June 30, 2020 | 3.198B |
December 31, 2019 | 3.278B |
June 30, 2019 | 3.327B |
June 30, 2019 | 3.327B |
December 31, 2018 | 2.892B |
June 30, 2018 | 2.899B |
June 30, 2018 | 2.899B |
December 31, 2017 | 2.860B |
June 30, 2017 | 2.816B |
June 30, 2017 | 2.816B |
December 31, 2016 | 2.643B |
June 30, 2016 | 2.547B |
June 30, 2016 | 2.547B |
December 31, 2015 | 2.478B |
Date | Value |
---|---|
June 30, 2015 | 2.473B |
June 30, 2015 | 2.473B |
December 31, 2014 | 2.171B |
June 30, 2014 | 2.344B |
June 30, 2014 | 2.344B |
December 31, 2013 | 1.744B |
June 30, 2013 | 1.960B |
June 30, 2013 | 1.960B |
December 31, 2012 | 1.240B |
June 30, 2012 | 1.681B |
June 30, 2012 | 1.681B |
December 31, 2011 | 1.290B |
June 30, 2011 | 1.994B |
June 30, 2011 | 1.994B |
December 31, 2010 | 1.221B |
June 30, 2010 | 1.705B |
December 31, 2009 | 1.254B |
June 30, 2009 | 1.764B |
December 31, 2008 | 985.32M |
June 30, 2008 | 1.912B |
June 30, 2008 | 1.912B |
December 31, 2007 | 1.048B |
June 30, 2007 | 1.742B |
June 30, 2007 | 1.742B |
December 31, 2006 | 1.814B |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
3.198B
Minimum
Jun 2020
4.605B
Maximum
Jun 2021
3.939B
Average
4.082B
Median
Jun 2022
Accounts Payable (Quarterly) Benchmarks
Novartis AG | 4.062B |
Pfizer Inc | 5.591B |
ADC Therapeutics SA | 14.32M |
Lonza Group Ltd | 557.18M |
Sarepta Therapeutics Inc | 91.54M |